Clinical Trial

Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Previously untreated patients with follicular lymphoma are treated with the ZGCVP regimen (zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, prednisolone) for 6 cycles.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-05.
Trial Details
NCT Number NCT06918015
Lead Sponsor Zhejiang Cancer Hospital
Conditions BTK Inhibitors, Follicular Lymphoma, Immunochemotherapy
Enrollment 58 participants
Start Date 2025-05-01
Primary Completion 2028-05-01 (estimated)
Study Completion 2030-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-15